Knight Therapeutics (TSX:GUD) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.01 by 400 percent. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $137.691 million which beat the analyst consensus estimate of $129.202 million by 6.57 percent. This is a 13.28 percent increase over sales of $121.548 million the same period last year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.